Get the Daily Brief
Latest Biotech News
PacBio cuts genome costs — reusable SMRT cells and new chemistry
Pacific Biosciences announced sequencing chemistry and consumable workflows that let customers wash and reuse SMRT cells on Revio instruments, plus a new Sprq‑Nx chemistry that boosts output and...
Benchling plugs Nvidia models into platform — AI for biomolecular R&D
Benchling integrated NVIDIA BioNeMo models and NIM microservices into its Benchling AI platform, enabling protein structure prediction (OpenFold2 initially) and laying groundwork for generative...
GoT‑Multi maps leukemia clones — single‑cell multi‑omics for FFPE
Weill Cornell Medicine and University of Adelaide researchers released GoT‑Multi, a high‑throughput single‑cell multi‑omics method compatible with FFPE samples that co‑detects multiple somatic...
Big pharma M&A: Novo buys Akero; BMS snaps up Orbital for CAR‑T push
Novo Nordisk agreed to acquire Akero Therapeutics in a deal that could top $5.2 billion to obtain the FGF21 analogue efruxifermin, which showed fibrosis regression signals in Phase II and...
Prime editing precision improved — Cas9 engineering reduces indels
Researchers engineered Cas9 variants to refine prime editing precision, developing successive editors (pPE, xPE, vPE) that reduce byproduct indels while maintaining efficiency across diverse...
Radiation plus immunotherapy gains ground — cervical and NSCLC data
Clinical data and pooled analyses reported that combining radiotherapy with immunotherapy improves outcomes in several difficult cancers. A phase Ib trial showed toripalimab added to concurrent...
Tubulis raises $361M — ADC program heads to clinic
Munich-based Tubulis closed a large financing to push its next‑generation antibody‑drug conjugates (ADCs) through clinical development. Reports show the company raised roughly $360–361 million in...
Kailera nets $600M — obesity program moves to global phase 3
Kailera Therapeutics secured a $600 million Series B to advance its dual‑targeting obesity program into global Phase 3 testing. The Bain Capital‑led round will fund pivotal development of...
Biocryst buys Astria for $700M — doubles down on HAE franchise
Biocryst Pharmaceuticals agreed to acquire Astria Therapeutics for about $700 million in cash and stock, adding Astria’s long‑acting injectable navenibart to Biocryst’s hereditary angioedema (HAE)...
J&J to spin out orthopedics — Depuy Synthes reborn
Johnson & Johnson announced plans to spin out its orthopedics unit as a standalone company to be called DePuy Synthes, part of a broader strategy to focus the parent company on higher‑growth...
PacBio cuts costs, wins Korean pangenome deal — long reads scale
Pacific Biosciences unveiled new chemistry and a reusable‑consumable workflow aimed at lowering per‑genome costs for high‑accuracy long‑read sequencing, and the company secured selection of its...
Benchling taps NVIDIA models — AI investors double down
Benchling integrated NVIDIA BioNeMo models and NIM microservices into its AI platform to give bench scientists direct access to protein structure prediction and other biomolecular models. The...
Bio‑Techne expands Oxford Nanopore pact — clinical nanopore assays next
Bio‑Techne extended and broadened its partnership with Oxford Nanopore to develop targeted enrichment kits and push nanopore sequencing deeper into clinical genetic testing for heritable...
SPT Labtech and 10x Genomics partner — single‑cell automation
SPT Labtech and 10x Genomics struck a strategic partnership to automate single‑cell workflows by combining SPT’s Firefly liquid handlers with 10x’s Chromium single‑cell chemistry and planned...
GoT‑Multi maps clonal evolution in FFPE — leukemia insights
Researchers introduced GoT‑Multi, a high‑throughput single‑cell multi‑omics tool that co‑detects multiple somatic genotypes and whole transcriptomes from formalin‑fixed, paraffin‑embedded (FFPE)...
FDA delays Denali review — Hunter syndrome decision pushed
The U.S. Food and Drug Administration extended its review of Denali Therapeutics’ biologics license application for tividenofusp alfa, a treatment for Hunter syndrome, by three months after...
BioCryst buys Astria to add long‑acting HAE shot: $700M deal
BioCryst Pharmaceuticals announced a cash-and-stock acquisition of Astria Therapeutics that values Astria at about $700 million. The deal transfers navenibart, a long-acting injectable plasma...
Kailera lands $600M to fast-track Zepbound‑like obesity shot: Series B lead
Kailera Therapeutics raised $600 million in a Series B round led by Bain Capital Private Equity to advance KAI‑9531 — a weekly injectable targeting the same receptors as Lilly’s Zepbound — into...
PacBio slashes cost per genome: reusable SMRT cells and new chemistry
Pacific Biosciences unveiled Sprq‑Nx chemistry and a program to allow select customers to reuse SMRT cell consumables on Revio instruments, promising up to 40% per‑genome savings for large...
Benchling embeds NVIDIA biomolecular AI: structure prediction in platform
Benchling announced integration of NVIDIA BioNeMo models and NIM microservices into its Benchling AI platform, enabling users to run OpenFold2‑based protein structure predictions and, over time,...